Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305657 | 0.98 | CES1 (0.50) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL305659 | 0.98 | CES1 (0.50) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL384895 | 0.89 | CES1 (0.64) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL3881031 | 0.89 | CES1 (0.64) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL384894 | 0.89 | CES1 (0.64) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL304071 | 0.87 | CES1 (0.61) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL304073 | 0.87 | CES1 (0.61) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL6523785 | 0.85 | CES2 (0.45) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL6523782 | 0.85 | CES2 (0.45) | CES1CES2AKR1B1CTBP2MEN1 | |
| SCHEMBL9355249 | 0.84 | CES2 (0.48) | CES1CES2AKR1B1CTBP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| WO-2013015388-A1 | NDM INHIBITOR | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 (JP) | 2013-01-31 | — | — | WO | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-0420884-A1 | COMPOUNDS CONTAINING AT LEAST THREE FUNCTIONAL ESTER GROUPS AND PROCESS FOR PRODUCING THEM | Chemische Fabrik Stockhausen GmbH (DE) | 1991-04-10 | — | — | EP | disclosed |
| WO-1989012040-A1 | COMPOUNDS CONTAINING AT LEAST THREE FUNCTIONAL ESTER GROUPS AND PROCESS FOR PRODUCING THEM | CHEMISCHE FABRIK STOCKHAUSEN GMBH (DE) | 1989-12-14 | — | — | WO | disclosed |
| EP-0345719-A2 | Compounds containing at least three functional ester groups, and process for their preparation | Chemische Fabrik Stockhausen GmbH (DE) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CES1 206/4885CES2 400/4885AKR1B1 2040/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | CES1 481/4885CES2 557/4885AKR1B1 1902/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | CES1 240/4885CES2 401/4885AKR1B1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.